Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial

Journal:

Nature Communications

Published:

2025-09-29

DOI:

10.1038/s41467-025-63579-9

Affiliations:

5

Authors:

10

Go to article

Institutions	Authors	Share
Ankyra Therapeutics, United States of America (USA)	5.000000	0.50
Massachusetts General Hospital (MGH), United States of America (USA)	2.000000	0.20
Providence Portland Medical Center, United States of America (USA)	1.000000	0.10
Princess Margaret Cancer Centre, U of T, Canada	1.000000	0.10
University of Pittsburgh (Pitt), United States of America (USA)	1.000000	0.10

Interested in Oncology and Carcinogenesis?